Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: ewolf who wrote (78)	6/5/2001 3:18:21 PM
From: Vector1	Read Replies (1) \| Respond to of 222

I have always like Bexxar. I think it is an excellent drug and has $300plus sales potential. What has been a nightmare is FDA approval of a novel drug. Specifically a drug that congutates a MAD with a radioactive isotope. Manufacturing is done by two different outsource agents and the FDA is looking very carefully. Not sure what has caused the price to rise. One possibility is word leaking out that the company has made progress with the FDA in terms of a resubmission. I personally think Zev has a problem because of lack of dosemitry. V1